AAAbdelrahman M. Alsharif

Abdelrahman M. Alsharif

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdelrahman M. Alsharif has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanotransduction unifies healthy nondiabetic wound healing over time by promoting a Cd14+/C1qa+ fibroblast subpopulation

    by Katharina S. Berryman, Abdelrahman M. Alsharif, Mansi Singh, Filiberto Quintero, Amelia B. Knochel, Maria Gracia Mora Pinos, Dharshan Sivaraj, Lulejeta Latifi, Fidel Saenz, Pedro Mora Pinos, et al.


  • Open Access

    Targeting circulating mechanoresponsive monocytes and macrophages to reduce fibrosis

    by Kellen Chen, Michelle Griffin, Dominic Henn, Katharina S. Berryman, Dharshan Sivaraj, Hudson C. Kussie, Clark A. Bonham, Eamonn McKenna, Maria Gracia Mora Pinos, Abdelrahman M. Alsharif, et al.

    In response to injury, a variety of different cells are recruited to sites of injury to facilitate healing. Recent studies have examined the importance of the heterogeneity of tissue resident fibroblasts and mechanical signalling pathways in healing and fibrosis. However, tissue repair and the inflammatory response also involves blood cells that are recruited from the circulation. Here we identify mechanoresponsive myeloid subpopulations present in scar and unwounded skin. We then modulate these subpopulations by manipulating mechanical strain in vivo and in vitro and find that specifically targeting myeloid mechanical signalling is sufficient to reduce the pro-fibrotic myeloid subpopulations and restore the native, anti-inflammatory subpopulations. In addition, myeloid-specific mechanotransduction ablation also downregulates downstream pro-fibrotic fibroblast transcriptional profiles, reducing scar formation. As inflammatory cells circulate and home to injury sites during the initial healing phases in all organs, focusing on mechanoresponsive myeloid subpopulations may generate additional directions for systemic immunomodulatory therapies to target fibrosis and other diseases across other internal organ systems.